Metformin May Improve RFS, OS in NSCLC Patients Who Are Overweight or Obese
www.cancertherapyadvisor.com
“Metformin may improve lung cancer-specific clinical outcomes in obese and overweight lung cancer patients and enhance immunotherapy efficacy in this growing population as well,” researchers concluded.

The study showed that metformin use was associated with improvements in overall survival (OS) and recurrence-free survival (RFS) for overweight and obese patients who had undergone lobectomy. Researchers also found that metformin was associated with longer progression-free survival (PFS) in overweight NSCLC patients treated with immune checkpoint inhibitors (ICIs).